Dabigatran: patient management in specific clinical settings.
Wien Klin Wochenschr
; 126(17-18): 503-8, 2014 Sep.
Article
em En
| MEDLINE
| ID: mdl-25138549
ABSTRACT
Dabigatran, a direct thrombin inhibitor, is licensed for the prevention of venous thromboembolism after knee and hip replacement, the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation and for the treatment of acute venous thromboembolism. As dabigatran has a favourable benefit-risk profile, it is being increasingly used. Dabigatran differs from vitamin K antagonists as regards its pharmacological characteristics and its impact on certain laboratory tests, and also in the lack of a direct antagonist that can reverse dabigatran-induced anticoagulation. In emergency settings such as acute bleeding, emergency surgery, acute coronary syndrome, thrombolysis for ischaemic stroke or overdosing, specific strategies are required. A working group of experts from various disciplines has developed strategies for the management of dabigatran-treated patients in emergency settings.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Benzimidazóis
/
Beta-Alanina
/
Guias de Prática Clínica como Assunto
/
Artroplastia de Substituição
/
Tromboembolia Venosa
/
Hemorragia
Idioma:
En
Ano de publicação:
2014
Tipo de documento:
Article